HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

M. Dowsett | M. Cheang | D. Rea | J. Robertson | M. Kissin | S. Johnston | R. Agarwal | I. Smith | J. Vaidya | K. Horgan | Z. Winters | D. Adamson | E. López-Knowles | C. Mortimer | R. Roylance | David M. Hwang | E. Schuster | A. Chakrabarti | R. Grieve | S. Thrush | J. Bliss | J. Fox | M. Shere | G. Sparrow | S. Laws | H. Sweetland | A. Jones | C. Crowley | Simon A. Smith | N. Bundred | Stephen Y. T. Chan | D. Ravichandran | M. Kelleher | R. Burcombe | M. Sibbering | H. Hamed | A. Kothari | C. Lewanski | C. Holcombe | L. Wyld | L. Kilburn | M. Bhattacharyya | T. Irvine | S. Cleator | P. Bhaskar | P. Donnelly | M. Hills | L. Barthelmes | I. Laidlaw | J. Doughty | S. Chatterjee | M. Carr | M. Churn | Jonathan Roberts | Douglas Ferguson | A. Alataki | Ruth Davis | H. Tovey | A. Evans | A. Skene | D. Wheatley | C. Murphy | M. Parton | Sankaran Narayanan | F. Hoar | S. McIntosh | F. Kenny | G. Dyke | S. Holt | G. Cunnick | R. Kennedy | A. Robinson | R. Todd | N. Gallegos | Ramachandra Prasad | C. Griffith | D. Thekkinkattil | S. Ellenbogen | R. Allerton | M. Winter | Hui Xiao | J. Barrett | R. Salman | R. Vidya | M. Bramley | M. Absar | S. Iqbal | A. Corder | P. Kneeshaw | R. Linforth | R. Coleman | G. Morani | R. Sutton | Brendan McFall | I. Khattak | A. Modi | M. Hogg | O. Hatcher | C. Abson | M. Hadaki | Michael Williams | A. Nejim | S. Ledwidge | Ambika Anand | R. Goranova | J. Naik | J. Newby | D. Crawford | Gilbert | A. Thorne | M. Ornstein | Ashraf Patel | Robert Leonard | M. Sharif | R. Johnson | J. Rees-Lee | J. Forrest | Jocelyn Adams | M. Quigley | N. Walji | Matthew J Hatton | Shobha Silva | M. Bergamino | A. Ball | A. Johri | C. Lee | Charlie Chan | C. Hinton | Ciaran Hollywood | C. Harding-Mackean | Duraisamy Ravichandran | E. Babu | Elaine Hyett | F. Ashkanani | H. Algurafi | Highes-Davies Prof | J. Kokan | Jitendra Parmar | Jonathan Dawson | Jull Donnelly | Kathleen M. Dunn | K. Chin | Kislaya Thakur | M. Kishore | M. Bews-Hair | M. Adelekan | Nicholas Williams | P. Crellin | P. Crane | Philip Walker | P. Sinha | Racheal Soulsby | R. Mehra | R. Cutress | Ravi Sharma | Riccardo Bonom | Robert Reichert | S. Chandrasekharan | Sarah Vesty | S. Seetharam | Shamaela Wahee | S. Pain | Simon Thomson | Simon Smith | S. Holt | Tamoor Usman | Tayo Johnson | T. Kovács | Urmila Barthkur | V. Pope | V. Brown | V. Muralikrishna | W. Samra | William Maxwell | S. Chan | Richard C. Johnson | Ian E. Smith | K. Thakur | Steve Holt | S. Silva | I. Smith

[1]  N. Harbeck,et al.  Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer , 2021, Cancers.

[2]  J. Cuzick,et al.  Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials , 2021, The Lancet. Oncology.

[3]  M. Dowsett,et al.  Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial , 2020, The Lancet. Oncology.

[4]  J. Vadgama,et al.  Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status , 2020, Journal of clinical medicine.

[5]  L. Carey,et al.  Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. , 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[6]  Charles M. Perou,et al.  HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. , 2020, Cancer treatment reviews.

[7]  Junkai Wang,et al.  Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). , 2019, Journal of the National Cancer Institute.

[8]  S. Hilsenbeck,et al.  HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. , 2019, Journal of the National Cancer Institute.

[9]  M. Dieci,et al.  De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[11]  M. Dowsett,et al.  Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations , 2018, British Journal of Cancer.

[12]  P. Gariglio,et al.  Mutant p53 gain of function induces HER2 over-expression in cancer cells , 2018, BMC Cancer.

[13]  C. Perou,et al.  Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. , 2018, Cancer treatment reviews.

[14]  Meenakshi Anurag,et al.  Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers , 2018, Clinical Cancer Research.

[15]  M. Dowsett,et al.  Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance , 2017, Nature Communications.

[16]  Marion Procter,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.

[17]  David Cameron,et al.  11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial , 2017, The Lancet.

[18]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[19]  Carsten Denkert,et al.  Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. , 2015, JAMA oncology.

[20]  Jong-Hyeon Jeong,et al.  Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Dowsett,et al.  Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance , 2013, Clinical Cancer Research.

[22]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[23]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[24]  M. Dowsett,et al.  Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer , 2010, Breast Cancer Research.

[25]  A. Thompson,et al.  p53 mutation, deprivation and poor prognosis in primary breast cancer , 2010, British Journal of Cancer.

[26]  J. Baselga,et al.  The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 , 2008, Nature Clinical Practice Oncology.

[27]  M. Dowsett,et al.  Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer , 2006, Clinical Cancer Research.

[28]  M. Dowsett,et al.  Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Jill P. Mesirov,et al.  Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data , 2003, Machine Learning.

[30]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[32]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[33]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[34]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .